![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOXICOLOGY
Department of Pharmacology and Toxicology, National Food Safety and Toxicology Center, Institute for Environmental Toxicology, Michigan State University, East Lansing, Michigan (J.P.L., J.F.M., P.E.G., R.A.R.); and Investigative Toxicology, Pharmacia Corporation, Kalamazoo, Michigan (G.N.C., G.L.C.)
Drug idiosyncrasy is an adverse event of unknown etiology that occurs in a small fraction of people taking a drug. Some idiosyncratic drug reactions may occur from episodic decreases in the threshold for drug hepatotoxicity. Previous studies in rats have shown that modest underlying inflammation triggered by bacterial lipopolysaccharide (LPS) can decrease the threshold for xenobiotic hepatotoxicity. The histamine-2 (H2)-receptor antagonist ranitidine (RAN) causes idiosyncratic reactions in people, with liver as a usual target. We tested the hypothesis that RAN could be rendered hepatotoxic in animals undergoing a modest inflammatory response. Male rats were treated with a nonhepatotoxic dose of LPS (44 x 106 endotoxin units/kg i.v.) or its vehicle and then 2 h later with a nonhepatotoxic dose of RAN (30 mg/kg i.v.) or its vehicle. Liver injury was evident only in animals treated with both RAN and LPS as estimated by increases in serum alanine aminotransferase, aspartate aminotransferase, and 
-glutamyl transferase activities within 6 h after RAN administration. LPS/RAN cotreatment resulted in midzonal liver lesions characterized by acute necrosuppurative hepatitis. Famotidine (FAM) is an H2-antagonist for which the propensity for idiosyncratic reactions is far less than RAN. Rats given LPS and FAM at a dose pharmacologically equipotent to that of RAN did not develop liver injury. In vitro, RAN sensitized hepatocytes to killing by cytotoxic products from activated neutrophils, whereas FAM lacked this ability. The results indicate that a response resembling human RAN idiosyncrasy can be reproduced in animals by RAN exposure during modest inflammation.
Address correspondence to: Dr. Robert A. Roth, Department of Pharmacology and Toxicology, B440 Life Sciences, Michigan State University, East Lansing, MI 48824. E-mail: rothr{at}msu.edu
This article has been cited by other articles:
|
|
 |
|
  W. Zou, S. S. Devi, E. Sparkenbaugh, H. S. Younis, R. A. Roth, and P. E. Ganey Hepatotoxic Interaction of Sulindac with Lipopolysaccharide: Role of the Hemostatic System Toxicol. Sci., March 1, 2009; 108(1): 184 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Shaw, A. C. Ditewig, J. F. Waring, M. J. Liguori, E. A. Blomme, P. E. Ganey, and R. A. Roth Coexposure of Mice to Trovafloxacin and Lipopolysaccharide, a Model of Idiosyncratic Hepatotoxicity, Results in a Unique Gene Expression Profile and Interferon Gamma-Dependent Liver Injury Toxicol. Sci., January 1, 2009; 107(1): 270 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Deng, M. J. Liguori, E. M. Sparkenbaugh, J. F. Waring, E. A. G. Blomme, P. E. Ganey, and R. A. Roth Gene Expression Profiles in Livers from Diclofenac-Treated Rats Reveal Intestinal Bacteria-Dependent and -Independent Pathways Associated with Liver Injury J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 634 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Deng, J. Lu, L. D. Lehman-McKeeman, E. Malle, D. L. Crandall, P. E. Ganey, and R. A. Roth p38 Mitogen-Activated Protein Kinase-Dependent Tumor Necrosis Factor-{alpha}-Converting Enzyme Is Important for Liver Injury in Hepatotoxic Interaction between Lipopolysaccharide and Ranitidine J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 144 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Tukov, J. P. Luyendyk, P. E. Ganey, and R. A. Roth The Role of Tumor Necrosis Factor Alpha in Lipopolysaccharide/Ranitidine-Induced Inflammatory Liver Injury Toxicol. Sci., November 1, 2007; 100(1): 267 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Shaw, M. J. Hopfensperger, P. E. Ganey, and R. A. Roth Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-Alpha Toxicol. Sci., November 1, 2007; 100(1): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Deng, J. P. Luyendyk, W. Zou, J. Lu, E. Malle, P. E. Ganey, and R. A. Roth Neutrophil Interaction with the Hemostatic System Contributes to Liver Injury in Rats Cotreated with Lipopolysaccharide and Ranitidine J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 852 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Roberts, P. E. Ganey, C. Ju, L. M. Kamendulis, I. Rusyn, and J. E. Klaunig Role of the Kupffer Cell in Mediating Hepatic Toxicity and Carcinogenesis Toxicol. Sci., March 1, 2007; 96(1): 2 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Luyendyk, L. D. Lehman-McKeeman, D. M. Nelson, V. M. Bhaskaran, T. P. Reilly, B. D. Car, G. H. Cantor, X. Deng, J. F. Maddox, P. E. Ganey, et al. Coagulation-Dependent Gene Expression and Liver Injury in Rats Given Lipopolysaccharide with Ranitidine but Not with Famotidine J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 635 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Luyendyk, L. D. Lehman-McKeeman, D. M. Nelson, V. M. Bhaskaran, T. P. Reilly, B. D. Car, G. H. Cantor, J. F. Maddox, P. E. Ganey, and R. A. Roth Unique Gene Expression and Hepatocellular Injury in the Lipopolysaccharide-Ranitidine Drug Idiosyncrasy Rat Model: Comparison with Famotidine Toxicol. Sci., April 1, 2006; 90(2): 569 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Waring, M. J. Liguori, J. P. Luyendyk, J. F. Maddox, P. E. Ganey, R. F. Stachlewitz, C. North, E. A. G. Blomme, and R. A. Roth Microarray Analysis of Lipopolysaccharide Potentiation of Trovafloxacin-Induced Liver Injury in Rats Suggests a Role for Proinflammatory Chemokines and Neutrophils J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1080 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Luyendyk, P. J. Shaw, C. D. Green, J. F. Maddox, P. E. Ganey, and R. A. Roth Coagulation-Mediated Hypoxia and Neutrophil-Dependent Hepatic Injury in Rats Given Lipopolysaccharide and Ranitidine J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1023 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Luyendyk, W. B. Mattes, L. D. Burgoon, T. R. Zacharewski, J. F. Maddox, G. N. Cosma, P. E. Ganey, and R. A. Roth Gene Expression Analysis Points to Hemostasis in Livers of Rats Cotreated with Lipopolysaccharide and Ranitidine Toxicol. Sci., July 1, 2004; 80(1): 203 - 213. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
